[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hair-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hair-loss":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,72,103,129,151,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100621301","scalp-hair-metabolomics-in-severe-obesity-100621301",false,"NCT07368842","Scalp Hair Metabolomics in Severe Obesity","Scalp Hair Metabolomics as a Novel Biomarker of Poor Metabolic Health in Individuals With Severe Obesity","Inclusion Criteria:\n\nAll subjects:\n\n1. Age 21-70 years\n2. Ability to provide informed consent\n\nHealthy weight controls:\n\n1. BMI of 18.5-24.9 kg\u002Fm2\n2. No chronic disease\n3. No long-term medications\n\nSevere obesity:\n\n1. BMI of \\> 32.5 kg\u002Fm2\n2. Scheduled to undergo bariatric surgery\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Any factors likely to limit adherence to study protocol\n3. Any history of autoimmune or scarring alopecia (eg. alopecia areata, discoid lupus, lichen planopilaris)",true,"ALL","21 Years","70 Years",{"count":21,"type":22},60,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to investigate how body weight and weight-loss surgery affect the natural chemicals found in scalp hair over time. We will also find out how common and severe hair thinning\u002Fhair loss and muscle loss are in the first 6 months after bariatric surgery.",[26,27,28,29],"Obesity & Overweight","Hair Loss","Metabolomics","Bariatric Surgery",[31,32,33,34],"obesity","hair loss","metabolomics","bariatric surgery","RECRUITING","2026-02-11",{"date":38,"type":39},"2026-02-13","ACTUAL",{"date":41,"type":39},"2026-02-07",{"date":43,"type":22},"2028-02",{"name":45,"class":46},"Singapore General Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":47},"100584113","clinical-study-to-evaluate-the-improvement-in-hair-loss-in-skin-of-color-treated-with-fractional-non-ablative-laser-100584113","NCT06885112","Clinical Study to Evaluate the Improvement in Hair Loss in Skin of Color Treated With Fractional Non-Ablative Laser","Inclusion Criteria:\n\n* Male and females between 21 - 55 years of age, inclusive.\n* Have Fitzpatrick Skin Type V to VI.\n* Have mild to moderate hair loss (Ludwig scale I-II for women, Norwood-Hamilton scale I-III for males)\n* Have self-reported thinning or hair loss for more than 6 months prior to screening but less than 5 years.\n* Clinically confirmed to have hair loss or thinning by the investigator via physical exam\n* Didn't receive hair-loss treatments or participated in a clinical study using 1565 NAFL device\n* In good general health, as determined by the Investigator\n* Willing and able to attend all study visits\n* Willing to maintain the same hair style as at the Screening Visit for the duration of the study. If coloring hair, willing to color it with the same frequency of usage as in the past, making sure not to color within 1-week before and 1-week after an in-office appointment\n* Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth)\n* Have a negative urine pregnancy test at screening and be using, and continue to use for the duration of the study, an effective contraception method (i.e., abstinence, barrier control, intrauterine device \\[IUD\\], or hormonal \\[estrogen\u002Fprogestin\\] contraceptives) for at least one menstrual cycle prior to study; if using IUD or hormonal contraceptives - then at least 2 years prior to screening, the initiation of which should not have been associated with initiation of hair loss\u002Fthinning.\n* Be willing and able to cooperate with the requirements of the study including images taken using a smart camera (multi-spectral) of several skin conditions\n* Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board\n* Be able to complete and understand the various rating instruments in English\n* Sponsor approved global image assessment of degree of thinning \u002F hair loss\n\nExclusion Criteria:\n\n* Clinical diagnosis of alopecia areata or scarring forms of alopecia\n* Patient is of skin type I-IV\n* Scalp hair loss on the treatment area, due to disease, injury, or medical therapy\n* Subjects who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy. Subjects of childbearing potential who are not using an approved method of birth control (oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence). Females of non-childbearing potential are defined as postmenopausal (e.g.: absence of menstrual bleeding for one year), hysterectomy or bilateral oophorectomy\n* Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), cuts and or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations\n* Participated in a previous 1565 NAFL study or treatment\n* History of surgical correction of hair loss on the scalp\u002F Hair transplants.\n* Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 90 days prior to the Baseline Visit.\n* Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 60 days prior to the Baseline Visit.\n* No history of burning, flaking, itching, and stinging of the scalp.\n* A chronic condition of high severity dandruff.\n* History of malignancy (except scc and bcc skin cancers) or undergoing chemotherapy or radiation treatments.\n* A known history of autoimmune thyroid disease, any other thyroid disorder\u002Fabnormality or other autoimmune disorders that in the opinion of the investigator may interfere with the study treatment.\n* A known history of untreated or uncontrolled depression or bipolar disease or any other condition that may impact the subject's participation.\n* Recent utilization of low level lasers for treating hair loss (past 6 months).\n* Has any condition that the treating investigator or PI thinks may put the Subject at risk or interfere with their participation in the study.\n* Is involved in any injury litigation claims.\n* Known history or recent bloodwork indicating iron deficiency (ferritin level is less than 30 ng\u002FmL), bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage \\>20 cigarettes\u002Fday.\n* Use of any medications that are known to potentially cause hair loss or affect hair growth, as determined by PI.","55 Years",{"count":56,"type":22},40,"INTERVENTIONAL",[59],"NA","The study incudes 18 to 55 y\u002Fo healthy subjects with moderate hair loss stage and Fitzpatrick skin type 5 or 6",[27],"2025-12-30",{"date":64,"type":39},"2026-01-02",{"date":66,"type":39},"2025-02-21",{"date":68,"type":22},"2027-02-21",{"name":70,"class":71},"Lumenis Be Ltd.","INDUSTRY",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":84,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100604169","phase-3-safety-and-efficacy-of-vdphl01-in-females-with-androgenetic-alopecia-aga-100604169","NCT07146022","Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia","Inclusion Criteria:\n\n* Subject is a female aged 18-65 years old;\n* Subject has a clinical diagnosis of mild to moderate AGA;\n* Subject is in good general health and has adequate renal and hepatic function;\n* Subject is willing to maintain at least 1\u002F4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study;\n* Subject is willing and able to administer the test article as directed and can read, understand, and complete the required questionnaires in English;\n* Subject is willing and able to swallow study drug whole;\n* Subject agrees to have a micro dot tattoo placed on their scalp;\n* Subject agrees to have this area photographed at study visits as indicated in the protocol.\n\nExclusion Criteria:\n\n* Subject has uncontrolled blood pressure or orthostatic hypotension;\n* Subject has symptoms or history of certain heart or thyroid conditions;\n* Subject has a history of or active hair loss due to conditions\u002Fdiseases other than AGA;\n* Subject has a current or recent history of dietary or weight changes, including use of GLP-1 agonists;\n* Subject has been diagnosed with COVID-19 within 16 weeks of baseline;\n* Subject has had previous radiation of the scalp;\n* Use of any of the following treatments within the indicated washout period before screening:\n\n  * Subject has used hormone replacement therapy or hormonal modulators within 6 months prior to screening\n  * Subject has used oral treatments for hair growth or that can affect hair growth, including systemic retinoids, within 6 months of screening\n  * Subject has used systemic calcium channel blockers or beta blockers within 12 weeks prior to screening\n  * Subject has used systemic cimetidine, ketoconazole, diazoxide, or corticosteroids (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening\n  * Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, injections, platelet rich plasma within 6 months prior to screening\n  * Subject has used any topical scalp treatments for hair growth within 12 weeks prior to screening\n  * Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study;\n  * Subject has any other condition that, in the investigator's opinion, interfere with the study","FEMALE","18 Years","65 Years",{"count":83,"type":22},552,[85],"PHASE3","This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA).\n\nAGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA.\n\nThis multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).",[88,89,90,91,27],"Androgenetic Alopecia (AGA)","Androgenetic Alopecia","AGA","Female Androgenetic Alopecia",[89,90,27],"2025-11-18",{"date":95,"type":39},"2025-11-24",{"date":97,"type":39},"2025-07-25",{"date":99,"type":22},"2028-01",{"name":101,"class":71},"Veradermics, Inc.",71,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":79,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":57,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":128},"100476518","study-to-assess-the-ability-of-the-portable-scalp-cooling-system-pscs-to-prevent-hair-loss-100476518","NCT05484973","Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss","A Post-market Multi-center Prospective Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss in Women Receiving Specific Chemotherapy Regimens for Breast Cancer Stages I-III.","Inclusion Criteria:\n\n1. Female patients ≥ 21 years of age\n2. Documented diagnosis of breast cancer, stage I, II, or III\n3. A planned taxane-containing CT regimen in the adjuvant or neoadjuvant setting with curative intent\n4. Concomitant agents may include trastuzumab, pertuzumab, or other CT agents such as cyclophosphamide, or carboplatin Note: Targeted and\u002For hormonal therapies intended for use after completion of the taxane-containing CT regimen will not be considered part of the study treatment period, and the AMMA PSCS will not be used during the post-CT targeted and\u002For hormonal therapy period\n5. Plan to complete the current CT regimen within six months\n6. At least two years out from the last CT causing hair loss with complete recovery of hair\n7. Karnofsky17 performance status 80% or greater\n8. Willing and able to sign informed consent for this study\n9. Willing and able to complete all required study procedures\n\nExclusion Criteria:\n\n1. Patients with female pattern baldness resembling picture I-3 or higher on the Savin scale\n2. Autoimmune disease affecting hair; e.g. alopecia areata, systemic lupus with associated hair loss, others\n3. A history of whole brain radiation\n4. Plans to use a CT regimen other than those specified in the inclusion criteria; specifically, a regimen not including paclitaxel or docetaxel or a regimen including an anthracycline (AC\u002FT, EC\u002FT, TAC, etc.)\n5. Hormone therapy concurrent with CT. Hormone therapy after CT is permitted\n6. Current and\u002For prior use of hair growth products, such as Nutrafol, minoxidil, and Keranique\n7. A serious concurrent infection or medical illness which would jeopardize the ability of the patient to complete the planned therapy and follow-up\n8. History of persistent grade 2 (or higher) alopecia induced by prior chemotherapeutic regimens\n9. History of and\u002For current exposure to other agents, drugs, device, or procedure that may cause hair loss\n10. Cold sensitivity\n11. Intercurrent life-threatening malignancy\n12. Evidence of untreated or poorly controlled hyperthyroidism or hypothyroidism\n13. History or current diagnosis of any of the following: Cold agglutinin disease, cryoglobulinemia, or cryofibrinogenemia\n14. Concurrent hematologic malignancy\n15. Participation in any other clinical investigation\n16. Concurrent treatment with any investigational agent\n17. Any reason the investigator does not believe the patient is a good candidate for the study",{"count":111,"type":22},99,[59],"The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservation after CT treatment.",[115,116,27,117],"Alopecia","Chemotherapy-induced Alopecia","Breast Cancer","2025-04-03",{"date":120,"type":39},"2025-04-06",{"date":122,"type":39},"2024-11-08",{"date":124,"type":22},"2026-09-30",{"name":126,"class":127},"Cooler Heads Care Inc.","OTHER_GOV",2,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":47},"100519676","blood-specimen-collection-for-laboratory-assay-research-100519676","NCT06046651","Blood Specimen Collection For Laboratory Assay Research","Inclusion Criteria:\n\n* Any gender, in good general health\n* Must be 18 years old or older, inclusive at enrollment\n* Must be willing to provide capillary blood samples via a fingerstick and venous blood samples, including self-collection and collection by a licensed healthcare professional\n* Must be able to read, understand, and willingly sign an Informed Consent Form (ICF) and complete a brief health questionnaire\n* Must be able to read, speak and understand English\n* Must be available to attend one study visit at Investigator's laboratory or a third-party laboratory designated by the Investigator or collect samples at home, at the discretion of the Investigator.\n\nExclusion Criteria:\n\n* Individuals who are unable to provide a blood sample due to any illness\n* Individuals participating in another research study, that the Investigator feels may compromise study outcomes\n* Individuals having an acute or chronic disease or medical condition, including pregnancy, which could excessively increase study risk in the opinion of the Investigator or compromise study outcomes\n* Individuals who are unlikely to be available for the duration of the study",{"count":136,"type":22},10000,"To collect lab data from capillary and venous blood specimens for use in analytical research studies to support the development and validation of laboratory procedures.",[139,140,27,141],"General; Metabolic Disorder","Sexual Dysfunction","Pathology","2024-11-13",{"date":144,"type":39},"2024-11-14",{"date":146,"type":39},"2023-08-16",{"date":148,"type":22},"2033-08-15",{"name":150,"class":71},"Roman Health Ventures Inc.",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":79,"minAge":80,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":57,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":170,"leadSponsor":172,"locationsCount":128},"100559150","alleviation-of-alopecia-in-breast-cancer-patient-using-synbiotics-formula-100559150","NCT06560385","Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula","A Pilot, Double-blind, Randomised, Placebo-controlled Trial on the Efficacy of a Synbiotic Formula (BLHK03) in Alleviating Chemotherapy-induced Alopecia (CIA) in Breast Cancer Patients","Inclusion Criteria:\n\n* Females aged between 18 and 60 years who are newly diagnosed with stage I, II or III breast cancer\n* Planned chemotherapy including an anthracycline or taxane to be completed within 6 months\n* Mentally capable to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Pre-existing female-pattern baldness resembling picture I-3 or higher on the Savin scale at baseline\n* History of hair transplantation, psoriasis or severe scalp infection\n* Undergoing or plan to receive scalp cooling\n* Plan for immunotherapy\n* Known pregnancy or lactating\n* Severe cardiac, hepatic, renal, pulmonary and haematic lesions or other life-threatening conditions\n* Use of antibiotics, probiotics or prebiotics one month prior to enrolment\n* No other alternative or complementary treatment for the cancer condition that may affect the gut microbiome analysis\n* History of allergy to probiotics or lactose\n* History of chemotherapy for other conditions","60 Years",{"count":56,"type":22},[59],"This study aims to explore the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients and the compositional and functional changes in the gut microbiome of breast cancer patients undergoing chemotherapy and treatment with BLHK03.",[117,27],[117,27,164,165],"Chemotherapy","Synbiotic","2024-09-11",{"date":168,"type":39},"2024-09-19",{"date":166,"type":39},{"date":171,"type":22},"2026-08-18",{"name":173,"class":71},"GenieBiome Limited",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":183,"studyType":23,"phases":4,"briefSummary":184,"conditions":185,"keywords":192,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":47},"100537860","systemic-treatments-for-alopecia-areata-registry-100537860","NCT06283316","Systemic Treatments for Alopecia Areata Registry","STA2R","Inclusion Criteria:\n\n* Diagnosed with alopecia areata;\n* Starting\u002Fusing a systemic treatment for alopecia areata;\n* Informed consent for registry participation obtained from patient and\u002For caretaker.\n\nExclusion Criteria:\n\n* Not sufficiently capable of understanding the Dutch language;\n* Not willing to participate.","16 Years",{"count":136,"type":22},"50 Years","A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.",[186,187,188,27,189,115,190,191],"Alopecia Areata","Alopecia Totalis","Alopecia Universalis","Hair Diseases","Alopecia Drugs","Autoimmune Diseases",[186,187,188,193,194],"Systemic treatment","Registry","2024-02-27",{"date":197,"type":39},"2024-02-28",{"date":199,"type":39},"2024-01-17",{"date":201,"type":22},"2099-12-31",{"name":203,"class":46},"Erasmus Medical Center"]